Robert Chan
Research Subjects
Robert Chan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Ana Sousa
GSK, Stockley Park, Uxbridge, UK
1 shared publication- Andrew Trigg
Clinical Statistics and Analytics, Bayer PLC, Reading, UK
1 shared publication - Anju Tripathi Peters
Division of Allergy and Immunology Feinberg School of Medicine Northwestern University Chicago Illinois USA
1 shared publication Azza Abdelkarim
Safety Evaluation and Risk Management, GSK, Warsaw, Poland
1 shared publicationBhabita Mayer
GSK, Stockley Park, Uxbridge, Middlesex, UK
1 shared publication- Brent A. Senior
Department of Otolaryngology–Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 10 January 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (1) , e70010
Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a recurrent inflammatory disease associated with several comorbidities and a significant disease burden for patients. Treatments include corticosteroids and sinonasal surgery, but these can be associated with the risk of adverse events and nasal polyp recurrence. Biologic treatments such as mepolizumab can be used as an add‐on treatment and are effective at reducing surgery and corticosteroid use.Main text: Patients with CRSwNP may be seen by a specialist in one of several different areas and often experience delayed diagnosis due to the need to see multiple physicians, as well as misdiagnosis resulting from lack of sufficient expertise within any one speciality. Multidisciplinary team (MDT) approaches have been shown to be effective in optimising the treatment and clinical management of other respiratory diseases, such as aspirin‐exacerbated respiratory disease and severe asthma. In CRSwNP, an MDT approach may reduce diagnostic delays, mitigate secondary disease burden, and reduce overprescription of corticosteroids and antibiotics.Conclusion: This article provides an overview of the patient perspective of MDTs, existing approaches and barriers to adoption, lessons learnt from allied and rare diseases, how to address under‐recognised aspects of CRSwNP, and other key considerations for developing an MDT approach.
- 10 January 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (1) , e70010
Top Cited PapersOpen AccessChronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a recurrent inflammatory disease associated with several comorbidities and a significant disease burden for patients. Treatments include corticosteroids and sinonasal surgery, but these can be associated with the risk of adverse events and nasal polyp recurrence. Biologic treatments such as mepolizumab can be used as an add‐on treatment and are effective at reducing surgery and corticosteroid use.Main text: Patients with CRSwNP may be seen by a specialist in one of several different areas and often experience delayed diagnosis due to the need to see multiple physicians, as well as misdiagnosis resulting from lack of sufficient expertise within any one speciality. Multidisciplinary team (MDT) approaches have been shown to be effective in optimising the treatment and clinical management of other respiratory diseases, such as aspirin‐exacerbated respiratory disease and severe asthma. In CRSwNP, an MDT approach may reduce diagnostic delays, mitigate secondary disease burden, and reduce overprescription of corticosteroids and antibiotics.Conclusion: This article provides an overview of the patient perspective of MDTs, existing approaches and barriers to adoption, lessons learnt from allied and rare diseases, how to address under‐recognised aspects of CRSwNP, and other key considerations for developing an MDT approach.
- Open Access
- 8 February 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.
- 8 February 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Open AccessEfficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.
- Open Access
- 1 February 2021
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (2) , AB126
Mepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study
- 1 February 2021
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (2) , AB126
Open AccessMepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study